Stephenson Harwood advises Lansen on Sicorten Plus acquisition
Stephenson Harwood has advised Lansen Pharmaceutical Holdings on the acquisition of the rights to sell Sicorten Plus, a cream used to treat inflammatory skin diseases, in China from Novartis, a multinational pharmaceutical company based in Basel, Switzerland.
Sign in or Register to continue reading this article
It's quick, easy and free!
Why register to The Lawyer
More relevant to you
News from Stephenson Harwood
News from The Lawyer
Briefings from Stephenson Harwood
This helpful one-page summary diagram shows the current expected timetable for Great Britain’s passenger rail franchises and concessions.
In Kays Hotels v Barclays Bank, the Commercial Court refused a strike-out application that was based on a bank’s argument that the claim was time-barred.
Analysis from The Lawyer
The Lawyer’s litigation reporter looks at the ongoing saga of the Tchenguiz litigation
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe